Patient background
| Dexamethasone | |||
|---|---|---|---|
| Total | Discretionary | Mandatory | |
| Variable | (n=163) | (n=89) | (n=74) |
| Median age (range), years | 68 (38–86) | 67 (38–81) | 69 (48–86) |
| Sex | |||
| Male | 98 | 57 | 41 |
| Female | 65 | 32 | 33 |
| Histology | |||
| Adenocarcinoma | 162 | 88 | 74 |
| Large | 1 | 1 | 0 |
| Stage | |||
| IIIA | 8 | 4 | 4 |
| IIIB | 18 | 14 | 4 |
| IV | 91 | 47 | 44 |
| Recurrence | 46 | 24 | 22 |
| Line of chemotherapy | |||
| First | 60 | 25 | 35 |
| Second | 50 | 32 | 18 |
| ≥Third | 53 | 32 | 21 |
| Regimens | |||
| CBDCA+PEM | 58 | 34 | 24 |
| CBDCA+PEM+Bev | 21 | 9 | 21 |
| PEM+Bev | 13 | 0 | 13 |
| PEM | 71 | 46 | 25 |
Bev, bevacizumab; CBDCA, carboplatin; PEM, pemetrexed.